The global Alpha-1 antitrypsin deficiency market is likely to garner a market value of US$ 3 Billion in 2023 and is expected to reach US$ 10 Billion by registering a CAGR of 12.8% in the forecast period 2023 to 2033. One of the primary reasons driving market expansion is the rising frequency of respiratory illnesses. Furthermore, the increased utilization of augmentation treatment is propelling market expansion.
This therapy includes extracting AAT protein from the blood plasma of a healthy donor in order to increase AAT levels in patients' respiratory tracts. In accordance with this, this treatment also slows the advancement of emphysema, reduces the frequency of exacerbations, and speeds up recovery time, all of which contribute to its growing popularity among both patients and healthcare professionals.
Increased personal disposable income and increased knowledge in developing nations about the availability of treatment choices will provide even more attractive market development potential. Rising worldwide medical tourism, an increase in the prescription for combination medicines, and a high potential for development in the undeveloped market will provide enough market growth possibilities.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 3 Billion |
| Anticipated Forecast Value (2033) | US$ 10 Billion |
| Projected Growth Rate (2023 to 2033) | 12.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for alpha-1 antitrypsin deficiency is projected to increase at a CAGR of 12.8% during the forecast period between 2023 and 2033, reaching a total of US$ 10 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 10%.
Numerous technical breakthroughs in diagnostic procedures and the development of novel technologies for the synthesis and purification of AAT. They are of higher grade and devoid of impurities such as viruses and germs. Other factors, such as increased Research and Development efforts and advancements in medical infrastructure, are expected to propel the market even more.
Increasing Research and Development Activities to Accelerate Market Growth
The increasing number of strategic collaborations between public and private market participants is driving an increase in the amount of Research and Development activities on a daily basis. These capabilities are being applied to the creation of innovative pharmaceuticals and medical technologies, which will drive the need for alpha1-antitrypsin deficiency therapy.
Furthermore, an increase in the number of genetic testing, blood tests, and biopsy tests, increased attempts by public and private groups to raise awareness, and a well-organized distribution network of top manufacturers will all contribute to the market's growth rate. Other factors, such as increased demand for effective medicines and expanding use of early diagnostic methods, will have a beneficial impact on the market's growth rate.
Increasing Healthcare Infrastructure Investment
Another key element impacting the growth rate of the alpha1-antitrypsin market is increased healthcare spending, which aids in infrastructure improvement. The expansion and growth of the healthcare business, particularly in developing nations, would encourage the usage and deployment of new and sophisticated medical technology, equipment, and pharmaceuticals. This will immediately boost the need for therapy of alpha1-antitrypsin deficiency.
Principal Consultant
Huge Investments in Research and Development to Stymie Market Augmentation
High expenses connected with research and development capabilities will emerge as one of the market's most significant limitations. The lack of knowledge and necessary infrastructure in developing and backward nations, as well as sluggish diagnostic rates of alpha1-antitrypsin deficiency, may further derail the market expansion. The slow pace of approval for medications and inhibitors, the scarcity of plasma fractionation capacity, and the rising number of patent expirations will all provide challenges to the market's growth rate.
Rising Healthcare Expenditure to Widen Profit Margins
Asia Pacific encompasses nations with a big patient pool and a high elderly population, thus the alpha1-antitrypsin deficiency industry in that region is driven by this factor. Over the projection period, the Asia Pacific regional sector is predicted to increase at a rapid pace.
The constant development of the medical tourism industry, rising healthcare expenditure, and bigger government initiatives pertaining to the development of healthcare infrastructure, primarily biotechnology, agriculture, and pharmacology, are just a few of the factors contributing to the rapid growth of the Asia Pacific alpha1-antitrypsin deficiency market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 12% in the assessment period 2023 to 2033.
Presence of Established Healthcare Infrastructure to Drive Market
The bulk of the worldwide alpha1-antitrypsin deficiency market was accounted for by North America. Because of the growing number of genetic disease therapeutics clinical trials in the area, North America is ruling the alpha1-antitrypsin deficiency market.
The presence of established healthcare infrastructure in the region, the availability of qualified specialists and advanced genetic testing equipment, high healthcare spending, and superior reimbursement rules are key reasons contributing to its substantial share. North America is expected to grow at a CAGR of 12.7% in the assessment period 2023-2033.
Expanding Patient Pool to fuel Market Growth
Because of the region's abundance of qualified specialists and modern genetic testing equipment, Europe is the second largest market for the alpha1-antitrypsin deficiency industry.
Europe is expected to develop at the fastest rate throughout the projection period owing to an expanding patient pool and more government backing. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 12.3% in the assessment period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Corticosteroid-based Treatments are highly sought after
The increased prevalence of chronic illnesses, an aging population, and rising Research and Development spending are the primary drivers of the corticosteroid segment's rise. The worldwide burden of chronic illnesses is expected to rise dramatically in the future years.
Furthermore, the growing senior population is more prone to chronic diseases that necessitate corticosteroid therapy for a number of ailments, which may drive the corticosteroid sector in the coming years further driving the Alpha-1 Antitrypsin Deficiency market.
Hospitals to be Primary Centers for Disbursing Treatments
In terms of application, hospitals led the Alpha-1 Antitrypsin Deficiency market in 2022. Patients mostly desire to be admitted to the hospital for therapy.
Moreover, the availability of highly experienced medical personnel who give a superior treatment experience has contributed to the rising market share over the next several years.
Key start-up players in the automotive axles are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Alpha-1 Antitrypsin Deficiency start-ups are as follows:
Key players in the Alpha-1 Antitrypsin Deficiency market are Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, and LFB Biomedicaments.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3 Billion |
| Market Value in 2033 | US$ 10 Billion |
| Growth Rate | CAGR of 12.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Product, Application, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Pfizer; Baxter; AstraZeneca; Grifols; Teva Pharmaceutical Industries; Boehringer Ingelheim; Kamada Ltd; GlaxoSmithKline; CSL Behring; LFB Biomedicaments |
| Customization | Available Upon Request |
FMI projects the global Alpha-1 Antitrypsin Deficiency market to expand at a 12.8% value CAGR by 2033
The global Alpha-1 Antitrypsin Deficiency market is estimated at a market value of US$ 3 Billion
The global Alpha-1 Antitrypsin Deficiency market is expected to garner a market value of US$ 10 Billion
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 12% in the assessment period 2023 to 2033.
Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, and LFB Biomedicaments are some prominent Alpha-1 Antitrypsin Deficiency manufacturers.
North America is expected to grow at a CAGR of 12.7% in the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 12.3% in the assessment period 2023 to 2033.
The hospital segment is expected to hold the largest market share for Alpha-1 Antitrypsin Deficiency in the forecast period 2023 to 2033.
1. Executive Summary | Alpha-1 Antitrypsin Deficiency Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033 5.3.1. Augmentation Therapy 5.3.2. Bronchodilators 5.3.3. Corticosteroids 5.3.4. Oxygen Therapy 5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Hospitals 6.3.2. Specialty Clinics 6.3.3. Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East & Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The US 8.2.1.2. Canada 8.2.2. By Product 8.2.3. By Application 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product 8.3.3. By Application 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product 9.2.3. By Application 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By Application 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. The UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Product 10.2.3. By Application 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Application 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Singapore 11.2.1.5. Thailand 11.2.1.6. Indonesia 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia Pacific 11.2.2. By Product 11.2.3. By Application 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Application 11.4. Key Takeaways 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Product 12.2.3. By Application 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Application 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. The US 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2022 13.1.2.1. By Product 13.1.2.2. By Application 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2022 13.2.2.1. By Product 13.2.2.2. By Application 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2022 13.3.2.1. By Product 13.3.2.2. By Application 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2022 13.4.2.1. By Product 13.4.2.2. By Application 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2022 13.5.2.1. By Product 13.5.2.2. By Application 13.6. The UK 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2022 13.6.2.1. By Product 13.6.2.2. By Application 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2022 13.7.2.1. By Product 13.7.2.2. By Application 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2022 13.8.2.1. By Product 13.8.2.2. By Application 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2022 13.9.2.1. By Product 13.9.2.2. By Application 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2022 13.10.2.1. By Product 13.10.2.2. By Application 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2022 13.11.2.1. By Product 13.11.2.2. By Application 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2022 13.12.2.1. By Product 13.12.2.2. By Application 13.13. Singapore 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2022 13.13.2.1. By Product 13.13.2.2. By Application 13.14. Thailand 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2022 13.14.2.1. By Product 13.14.2.2. By Application 13.15. Indonesia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2022 13.15.2.1. By Product 13.15.2.2. By Application 13.16. Australia 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2022 13.16.2.1. By Product 13.16.2.2. By Application 13.17. New Zealand 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2022 13.17.2.1. By Product 13.17.2.2. By Application 13.18. GCC Countries 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2022 13.18.2.1. By Product 13.18.2.2. By Application 13.19. South Africa 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2022 13.19.2.1. By Product 13.19.2.2. By Application 13.20. Israel 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2022 13.20.2.1. By Product 13.20.2.2. By Application 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Product 14.3.3. By Application 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Pfizer 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Baxter 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. AstraZeneca 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Grifols 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Teva Pharmaceutical Industries 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Boehringer Ingelheim 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Kamada Ltd 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. GlaxoSmithKline 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. CSL Behring 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. LFB Biomedicaments 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Alpha-1 Antitrypsin Deficiency Market
